66 CHAPTER 4 Results Retrieved articles Our search identified a total of 14 articles, which included RCTs, patients’ perspectives, and literature overviews of our topic. Six additional articles (five trials and one patients’ perspective study), one abstract and results presented at the Advances in Targeted Therapies meeting that took place in Marseille, France in March 2022 were included manually by the authors. Randomized-controlled trials In total, we thoroughly reviewed ten RCTs (Table 1): • one RCT in seropositive first-degree relatives of RA patients, who were treated with conventional synthetic (cs)DMARD (StopRA study), • six RCTs in arthralgia patients, where participants were treated with glucocorticoids (dexamethasone trial), csDMARDs (TREAT EARLIER study), biological (b) DMARDs (ARIAA trial, APIPPRA trial, PRAIRI trial), and statins (STAPRA study), • two trials in UA, in which patients were treated with csDMARDs (PROMPT study) and bDMARDs (ADJUST trial), • one trial in inflammatory arthritis, in which patients were treated with glucocorticoids (SAVE study). Figure 2 shows the timeline (Figure 2A) of the included trials and their distribution in relation to the different (pre-clinical) phases of RA (Figure 2B).
RkJQdWJsaXNoZXIy MTk4NDMw